Rapamycin (Sirolimus)

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989,NSC-2260804

Rapamycin (Sirolimus) Chemical Structure

Molecular Weight(MW): 914.18

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
In DMSO USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 63 Publications

12 Customer Reviews

  • Protein blots showing MYC expression in naive and persister cells after 3 d of treatment with 2 uM AKT inhibitor MK-2206 (AKTi) or 10 nM mTOR inhibitor rapamycin (Rapa).

    Nat Genet 2014 46(4), 364-70. Rapamycin (Sirolimus) purchased from Selleck.

    Cooperative Effects of AR and mTOR Inhibition In Vitro and In Vivo (A) In vitro response of Pten null;Ar+ murine (CaP8) and human (LNCaP) prostate cancer cells to AR knockdown (sh-AR) or pharmacological inhibition of AR (MDV3100, 10 nM) with and without rapamycin (R: 1 nM) treatment (Sc, control sh oligo). (B and D) In vivo response to treatments with castration, MDV3100, rapamycin, or their combinations as measured by cell proliferation (Ki67+cells) and (C and D) tumor burden in Pb-Cre+;-PtenL/L and Pb-Cre+;PtenL/L:ArL/Y mutants. Scale bars represent 2 mm (C), 200 mm (D), and 75 mm (D, inset). Error bars represent mean ±SD.

    Cancer Cell 2011 19(6), 792-804. Rapamycin (Sirolimus) purchased from Selleck.

  • 48 hours after addition of rapamycin(150 nM), the cells were imaged as described in Figure A to detect formation of punctuated GFP-LC3 structure. Quantification represented the ratio of GFP-LC3 punctuated positive cell to the total cell counted(Figure B).

    Cell Res 2012 22(6), 1003-21. Rapamycin (Sirolimus) purchased from Selleck.

    H4-LC3-GFP cells were treated with 1 nM IFNA2 for the indicated periods in the presence of 200 nM rapamycin. Images of the cells were collected using an ArrayScan HCS 4.0 Reader. Representative cells are shown. The average spot intensity in 500 cells from each indicated sample was determined. Data are displayed as means ?SD of the spot intensity per cell (below). RLU, relative leight unit.

    Autophagy 2015 11(4), 617-28. Rapamycin (Sirolimus) purchased from Selleck.

  • Rheb Induces Phospho-eIF2a Independent of mTORC1 and Promotes Phospho-eIF2a Predominantly through PERK (A) Western blotting of indicated proteins of HEK293 expressing cDNAs of myc (control) or myc-Rheb WT were grown in DMEM with serum (+) or without serum (-) or pretreated with the inhibitors rapamycin (250 nM) or DMSO (0.5%, control). (B) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with rapamycin or DMSO as in (A). (C) Western blotting of indicated proteins in HEK293 cells expressing myc or myc-Rheb and pretreated with inhibitors of MAPK (PD98059, 50 mM) or PI3K (wortmannin, 100 nM), rapamycin, or DMSO.

    Cell Rep 2015 10.1016/j.celrep.2015.01.014. Rapamycin (Sirolimus) purchased from Selleck.

    Autophagy induced by PL-0N and PL may restrict LPS-induced inflammatory responses in RAW264.7 cells. LPS induced autophagy in RAW264.7 cells. Cells were incubated with 1 mM 3-MA or 10 uM Rapamycin in the absence or presence of LPS (1 ug/mL) for 16 h. Then immunofluorescence for LC3 was visualized using a Zeiss LSM 710 confocal microscope.

    Biochem Pharmacol 2015 95(3), 156-69. Rapamycin (Sirolimus) purchased from Selleck.

  • Inhibition of mTOR activity may be responsible for sorafenib-induced down-regulation of survivin. H1299 cells were treated with the indicated concentration of RAD001 or Rapamycin for 48 h. Then H1299 cells were incubated with or without 5 μM sorafenib, with or without 5 μM RAD001, and with or without 2 μM rapamycin for 48 h.  The indicated protein levels were determined by Western blot analysis. β-Actin protein levels were measured as loading controls.

     

     

    Biochem Pharmacol 2011 82, 216-226. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin (RPM) inhibits OA-induced lipogenesis. Male SD rats were divided into three groups, and then treated as follows for seven days: group I (control; Ctrl), normal diet + vehicle; group II (OA), 1% OA diet + vehicle; group III (OA + RPM), 1% OA diet + RPM. (A) Hepatic TG concentrations were determined using the serum triglyceride determination kit. (B) Fixed liver sections were subjected to HE and Oil Red O staining as well as immunohistochemistry assays with SREBP-1 antibody. Representative microphotographs of liver specimens from all groups of rats are shown. (C) The levels of mRNA of the indicated genes involved in lipogenesis were determined by real-time PCR. Each bar represents the mean ±SE of the results obtained from six rats. * P < 0.05, ** P < 0.01, *** P < 0.001.

    J Lipid Res 2011 52, 1617-1625. Rapamycin (Sirolimus) purchased from Selleck.

  • Immunophilins participate in SOCE activation by CN-dependent but also CN-independent signaling pathways. Fura-2 loaded platelets were suspended in HBS and subsequently incubated at 37oC for 30 min with rapamycin (500 nM). Once incubation time was over, platelets were stimulated with TG (200 nM) in a calcium free-HBS (EGTA 100 μM was added as indicated the by arrowhead) and 4 min later CaCl2 (300 µM) was added to visualized calcium entry. Changes in fura-2 fluorescence were monitored using the 340/380nm ratio and calibrated in terms of [Ca2+]c . Traces are representative of four to six independent experiments. *,**, *** represents p < 0.05, p < 0.01 and p <0.001, respect control platelets.

    Biochim Biophys Acta 2013 1833(3), 652-62. Rapamycin (Sirolimus) purchased from Selleck.

    Tuberc Respir Dis 2013 75(1), 9-17. Rapamycin (Sirolimus) purchased from Selleck.

  • 2013 Dr. Zhang of Tianjin Medical University. Rapamycin (Sirolimus) purchased from Selleck.

    Rapamycin inhibits growth-dependent TCTP induction. Cells were serum-starved for 24h and restimulated with 20% FBS for the indicated times in the presence or absence of rapamycin. The graph shows the relative TCTP signal, corrected for the loading control.

    2011 Dr.Ulrich Bommer of University of Wollongong. Rapamycin (Sirolimus) purchased from Selleck.

Purity & Quality Control

Choose Selective mTOR Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NYG5N5U5S3m2b4TvfIlkKEG|c3H5 NUS1cXNkOTBibl2= M{HJeVczKGh? MY\EUXNQ M4Hu[XBwfGWwdHnheIV{KGOjbYD0c5Rp\WOrbj3pcoR2[2WmIHP5eI91d3irY3n0fS=> NV3aeZlpOjR7MEC4O|M>
HT-29 M4DCOmN6fG:2b4jpZ{BCe3OjeR?= MXqxNEBvVQ>? MVy3NkBp NXLTcHhmTE2VTx?= M3XRfXBwfGWwdHnheIV{KGSrZ3n0c5hqdi2rbnT1Z4VlKGO7dH;0c5hq[2m2eR?= Mk[zNlQ6ODB6N{O=
HT-29 NYDZNo4{S3m2b4TvfIlkKEG|c3H5 MmjwNVAhdk1? NWLCSGJGPzJiaB?= MWfEUXNQ NES5NJdRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? MljYNlQ6ODB6N{O=
PC3 NXWwfVg5U2mwYYPlJGF{e2G7 NEnadYEyODBibl2= M2rzTFEhcA>? MUjEUXNQ MkPTVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6= MnfoNlE6Pzh4OEO=
PC3 MV\LbY5ie2ViQYPzZZk> M1[0WlExOCCwTR?= MWmxJIg> M{XiWWROW09? NUP5OIpZTG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36= Mon5NlE6Pzh4OEO=
PC3 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;XXVEvPSEQvF2= NHPxZ5IyKGh? MkTOSG1UVw>? M3y5Umlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNid3n0bEBKSzVyIH;mJFwyOCCwTR?= M2DRNFIyQTd6Nkiz
HEK293 M3zPemZ2dmO2aX;uJGF{e2G7 MUGxNFAhdk1? MUK4JIg> Ml2wSG1UVw>? NE\rXI1KdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2= M3TES|IyPTN7M{Cx
BT-20 MkjaT4lv[XOnIFHzd4F6 M1H1T|IxKM7:TR?= MVXEUXNQ NEDoeHlFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?= MUiyNVM2OzV3MR?=
U937 NVv3XWY5SW62aXLhZ5RmemmjbDDBd5NigQ>? MVe1NEDPxE1? NIPBOVQ1QCCq NXKwNJlnTE2VTx?= MYPJcoR2[2W|IHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEB4cWymIIT5dIUhVGWpaX;u[Yxt[SCybnX1cY9xcGmuYTDQbIlt[WSnbIDobYEuOSCMUkOyJIlvKFV7M{egZ4VtdHN? Mn7rNlEyPDJzME[=
U937 Mk\iRY51cWKjY4TldolidCCDc4PhfS=> NWC4SYo6PTBizszN NUPlR3VLPDhiaB?= MXfEUXNQ NYf6cIF3TG:nczDuc5QhcW6mdXPlJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCCPSWCgdJJwfGWrbj3k[YZq[2mnboSgUIVocW:wZXzsZUBxdmW3bX;wbIlt[SCMUkOyMVIhcW5iVUmzO{Bk\Wyucx?= Ml3lNlEyPDJzME[=
U937 NHLIXZRCdnSrYnHjeIVzcWGuIFHzd4F6 NHHoUmw2OCEQvF2= MmjOOFghcA>? MXHEUXNQ NF7i[o5Fd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KEW|Y3jldolkcGmjIHPvcIkhUEJzMEGgbY4hXTl|NzDj[Yxtew>? NHzxRoUzOTF2MkGwOi=>
MCF-7 M1LUXGF2fG:yaHHnfUBCe3OjeR?= NV3mRnVJOzBibl2= M3;ESVQhcA>? MVXEUXNQ MlLLTY5lfWOnczDheZRweGijZ4m= MXSyNFAzQDF|NB?=
U87MG MW\LbY5ie2ViQYPzZZk> NULvUVI2OSEQvF2= NWLURVl7PiCq NUfBRpQxTE2VTx?= M{n0N3BwfGWwdHz5JIlvcGmkaYTzJI1VV1JvbXXkbYF1\WRiU{[gdIhwe3Cqb4L5cIF1cW:w M2HVSFE6QDR6NEC0
U87MG MX;LbY5ie2ViQYPzZZk> M4W5S|Eh|ryP NHvXZ2c3KGh? M{jx[GROW09? MlGzVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= M3\SfFE6QDR6NEC0
U87MG M1PhVmtqdmG|ZTDBd5NigQ>? Mo[zNUDPxE1? MVy2JIg> NUfIUXVVTE2VTx?= MmewSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MnnLNVk5PDh2MES=
U87MG NWLNdod1U2mwYYPlJGF{e2G7 M2ftZlEh|ryP MoG3OkBp Mm[zSG1UVw>? NVLmNXl{TG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w M{nreFE6QDR6NEC0
COS7 cells expressing EGFP-HDQ74/rheb NF7jRYJCfXSxcHjh[5khSXO|YYm= M3nKcVAvOiEQvF2= NXTwb2s1OjRiaB?= M2\EUWROW09? NXnTbJVFUW6mdXPld{BifXSxcHjh[5k> M3SzeFE5OzlzOUS5
COS7 cells expressing EGFP-LC3 M2nsXGF2fG:yaHHnfUBCe3OjeR?= NGfOW2cxNjJizszN MUmyOEBp MnOwSG1UVw>? MYHJcoR2[2W|IHH1eI9xcGGpeR?= M4D4RVE5OzlzOUS5
H4 MYHGeY5kfGmxbjDBd5NigQ>? MoDxNE4zKM7:TR?= NX;aS|JIOjRiaB?= Ml;vSG1UVw>? NV3EUIh1UW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>? MVixPFAzPDV6NB?=
HeLa MV;GeY5kfGmxbjDBd5NigQ>? Ml\HNVAxKG6P MWGzOkBp MUfEUXNQ NFjJXIhKdmS3Y3XzJGZTSiCNMkC5OXAtKFR{MEm4UEwhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MmH6NVc2PjN|OEW=
HeLa NYHsO3c3TnWwY4Tpc44hSXO|YYm= NF7VeHcyODBibl2= MYezOkBp MYDEUXNQ MWPJcoR2[2W|IF\SRkBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> MkSxNVc2PjN|OEW=
HeLa MlHISpVv[3Srb36gRZN{[Xl? MVixNFAhdk1? M{\ue|M3KGh? NFXQSndFVVOR NYH5SW13UW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v M1XHflE4PTZ|M{i1
SYF NFiwNWhHfW6ldHnvckBCe3OjeR?= NUn3b5lTOTByIH7N MYOyOEBp NVuzclc5TE2VTx?= M4Ly[Glv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=> NV3EelVTOTd3NkOzPFU>
SYF NUnzeo4xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrIR3QyODBibl2= M1zkSVI1KGh? MoHDSG1UVw>? M3O0dWlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO= MWGxO|U3OzN6NR?=
HEK293T NWPLXGxzSW62aY\pdoFtKEG|c3H5 M{\MU|Ehdk1? NIDwNnI1KGR? NIfiVVRFVVOR MWLJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?= NUjDXVRqOTd2OEW1NFE>
HEK293T NITHPY9CdnSrdnnyZYwhSXO|YYm= NIHYWXEyKG6P NFnrSWs1KGR? MXXEUXNQ Mnr0TY5lfWOnczDhcpRqfmm{YXygZYN1cX[rdImgZYdicW6|dDDITXYyKFh2IIfpeIghTUN3MDDv[kAxNjNibl2= NYHkPYpEOTd2OEW1NFE>
PBMC NXvv[JVUTnWwY4Tpc44hSXO|YYm= M2\ZelEhdk1? MlfHNVQh\A>? NYnjZnJXTE2VTx?= MmXCVoVlfWOnczDDR3I2KGSnboPpeJk> NH;3bFYyPzR6NUWwNS=>
PBMC NVTHfG9PTnWwY4Tpc44hSXO|YYm= NFfuW5YyKG6P NF3HTI0yPCCm NYnKZ|YzTE2VTx?= M1;VfGRw\XNibn;0JIFn\mWldDDDXGNTPCCmZX7zbZR6 MXKxO|Q5PTVyMR?=
HEK293 cells MYHLbY5ie2ViQYPzZZk> MV[1NEBvVQ>? MXS0OUBucW5? M4Gyb2ROW09? Mne0TY5pcWKrdIOgcXRQWiCtaX7hd4Uh[WO2aY\peJkhf2m2aDDJR|UxKG:oIECuNUBvVQ>? MUOxO|M2ODl3Mx?=
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M{LxRmZ2dmO2aX;uJGF{e2G7 M4fPW|ExOCCwTR?= MXW0JIg> Mm\hSG1UVw>? NF7Y[FBKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>? MYKxO|EzQDJ4Mh?=
Human mixed lymphocyte M4noVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLKS|FlPSCwTR?= MmGySG1UVw>? MknRTWM2OD1zLk[gcm0v NXe5bIx{OTZzOEW4OlU>
Lewis rat lymph node cells NFLMb5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfsWJM2KM7:TR?= M{LZXmROW09? M3z4XGlEPTB;Mj62JO69VQ>? M{XxU|E3OTh3OE[1
cells from the thymus of normal BALB/c mice M3XTeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUP4RYF6OTBibl2= MWe3NkBp M3W3PWROW09? MXvJcohq[mm2czDsfY1xcG:ycn;sbYZmemG2aX;uJEhNSUZrIIfpeIghUUN3MDDv[kA{KG6P MVKxNFAzOTl2OB?=
MRK-nu-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DEeGlEPTB;MD64OFUheE1? NHrhR3lUSU6JRWK=
OCUB-M NV7rcmRwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTVwMkSgdG0> MVnTRW5ITVJ?
SF539 MnzsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nWbmlEPTB;MUGuOkBxVQ>? NFPrWIdUSU6JRWK=
ES4 NIHwZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\UTWM2OD1{MT61JJBO MW\TRW5ITVJ?
RL95-2 M3W5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjETWM2OD1zMEegdG0> M1fFTnNCVkeHUh?=
LC-2-ad NH3EdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjjRotKSzVyPUSyN{BxVQ>? MmfxV2FPT0WU
Daudi NFvnO3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C3O2lEPTB;NEO0JJBO NYXNbplqW0GQR1XS
NTERA-S-cl-D1 NFXQS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO2U25KSzVyPUS0N{BxVQ>? MVzTRW5ITVJ?
OS-RC-2 MlTTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPtTGRlUUN3ME22OVIheE1? NGPDNGZUSU6JRWK=
VA-ES-BJ MlHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HkOWlEPTB;N{KzJJBO M2nzSXNCVkeHUh?=
GR-ST NWK2dlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXhTnBSUUN3ME24OFYheE1? NIHtR|lUSU6JRWK=
SW872 NETXXYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjpXJEzUUN3ME24OFYheE1? MWnTRW5ITVJ?
NOS-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTh5MTDwUS=> NHPYO3NUSU6JRWK=
MC116 MnLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLiTWM2OD17OEWgdG0> NGHES|BUSU6JRWK=
NCI-H1355 NXK5dJJvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzyN4lEUUN3ME2xMlAyKG6P NV7ONnB{W0GQR1XS
RPMI-8226 NHLTdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi1TWM2OD1zLkG5JI5O MkK3V2FPT0WU
TE-15 M4W0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTtRoxyUUN3ME2xMlM3KG6P MmT3V2FPT0WU
Ramos-2G6-4C10 Mm\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\FT2lEPTB;MT60OkBvVQ>? Mm\aV2FPT0WU
KU812 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[5UW0zUUN3ME2yMlAyKG6P NYnlUVZ4W0GQR1XS
EW-1 NGTXfHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnH6TWM2OD1{LkG3JI5O MkDWV2FPT0WU
KS-1 NI[3bWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r1SGlEPTB;Mj60OUBvVQ>? Mlm3V2FPT0WU
SK-LMS-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfD[W97UUN3ME2yMlQ6KG6P M3fWRXNCVkeHUh?=
TGBC1TKB MmjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTJwNkmgcm0> NWrvfXQ{W0GQR1XS
TE-6 NVPReHFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\5b2lEPTB;Mj63O{BvVQ>? MmmyV2FPT0WU
ETK-1 MnjXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLTVmVKSzVyPUKuPFIhdk1? MW\TRW5ITVJ?
BE-13 Mn7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTJwOUmgcm0> MVHTRW5ITVJ?
A3-KAW NVvFdmx[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2rnVmlEPTB;Mj65PUBvVQ>? NHznbVJUSU6JRWK=
TE-10 NXXDOYZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX[wd4l4UUN3ME2zMlMhdk1? MX7TRW5ITVJ?
DOHH-2 Mn7qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2WwNWlEPTB;Mz6zOUBvVQ>? MnTmV2FPT0WU
ES6 NIPtOIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1n1b2lEPTB;Mz60N{BvVQ>? MnHEV2FPT0WU
OPM-2 NFq5RZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYO1TXRuUUN3ME20MlE2KG6P MlHWV2FPT0WU
SH-4 M4HOWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTRwM{Sgcm0> NEi0RWtUSU6JRWK=
NB13 NFXrcYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTRwM{[gcm0> NXjTcGEyW0GQR1XS
HUTU-80 NG\2[YFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHGTWM2OD12LkSyJI5O MoHWV2FPT0WU
CCRF-CEM Mlf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX3JR|UxRTRwOUSgcm0> NIHxSmNUSU6JRWK=
TGBC24TKB MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHKU|VKSzVyPUWuOVEhdk1? MonBV2FPT0WU
697 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MomwTWM2OD14LkK4JI5O MmTyV2FPT0WU
J-RT3-T3-5 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTZwNE[gcm0> NW[2T4xVW0GQR1XS
KALS-1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jBcGlEPTB;Nj61OkBvVQ>? MV\TRW5ITVJ?
no-10 NWT2S3pCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTdwMkmgcm0> MnXuV2FPT0WU
SK-NEP-1 MmX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLOZmlXUUN3ME24Mlc6KG6P NY\SZnY4W0GQR1XS
L-540 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVjJR|UxRTFyLkSyJI5O NEjNZ29USU6JRWK=
JiyoyeP-2003 Moq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoX3TWM2OD1zMD65OEBvVQ>? MYLTRW5ITVJ?
HH Ml7RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvPTWM2OD1zMT6zPUBvVQ>? MY\TRW5ITVJ?
SR M13GdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\pNmlpUUN3ME2xNU41PSCwTR?= Mn2zV2FPT0WU
QIMR-WIL MnLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nQUGlEPTB;MUGuPFUhdk1? MWPTRW5ITVJ?
A4-Fuk NVOwZ2E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF|LkGyJI5O NXTVW5drW0GQR1XS
CESS M17HVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXVTWM2OD1zMz6xN{BvVQ>? MlfmV2FPT0WU
KE-37 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYjGS3dRUUN3ME2xOk4xPyCwTR?= MYLTRW5ITVJ?
SK-UT-1 Mmq5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXiydpJOUUN3ME2xOk45OSCwTR?= NEjyWG9USU6JRWK=
SIG-M5 NWroOHByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDBTGpKSzVyPUG3MlI2KG6P NHj3bZlUSU6JRWK=
HT MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXX6fY1PUUN3ME2xO{43KG6P NHX2ZlBUSU6JRWK=
DEL MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LHVWlEPTB;MUeuPVkhdk1? M1HwenNCVkeHUh?=
SK-PN-DW MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTJyLkKzJI5O NED0bWxUSU6JRWK=
RPMI-8402 Mn7wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJzLke3JI5O M1;tOHNCVkeHUh?=
RPMI-6666 NUHyWIRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLGTWM2OD1{ND60NkBvVQ>? NFnBZ2tUSU6JRWK=
NCI-H720 NGrDeFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M16y[WlEPTB;MkWuOFEhdk1? MVzTRW5ITVJ?
EW-16 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv6TWM2OD1{Nj64O{BvVQ>? M2DyUnNCVkeHUh?=
BL-70 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVGzbYNWUUN3ME2yPE4{QCCwTR?= NIfRNZJUSU6JRWK=
SF126 NHnVe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDNVpd7UUN3ME2zNE4{QCCwTR?= NFjFWphUSU6JRWK=
BC-1 NXHOXnhMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWja[Wd{UUN3ME2zNU4zPiCwTR?= NWq1PHpuW0GQR1XS
MHH-PREB-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3ORZJKSzVyPUOyMlQ1KG6P NX7ENoNiW0GQR1XS
A101D NF7XUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnf6TWM2OD1|Mj62NkBvVQ>? MmryV2FPT0WU
NMC-G1 NXXSOVJbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jFWmlEPTB;M{OuOlchdk1? MWrTRW5ITVJ?
LB1047-RCC MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnmd21KSzVyPUO0MlY6KG6P NHS3bW1USU6JRWK=
EM-2 NUjqSmU6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoHUTWM2OD1|OD61N{BvVQ>? M{HOUnNCVkeHUh?=
COLO-684 MmT2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXnJR|UxRTN7Lkigcm0> MmT0V2FPT0WU
Becker MmXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWDvV3lDUUN3ME20NU4xPSCwTR?= MXTTRW5ITVJ?
BL-41 NFmzdXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\uS2JKSzVyPUSzMlY3KG6P M4\MOHNCVkeHUh?=
MDA-MB-134-VI NIHMSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWD5NnRNUUN3ME20OE4xOiCwTR?= NHm4PHlUSU6JRWK=
L-363 NGLXNItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGexfohKSzVyPUS0Mlc{KG6P Mn3vV2FPT0WU
ECC4 NIHPWGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvBSlBuUUN3ME20OE44QCCwTR?= MV\TRW5ITVJ?
A388 NWGxSFc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnKyTWM2OD12ND64NkBvVQ>? Mnj2V2FPT0WU
HEL Mlj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLYTWM2OD12OT63PUBvVQ>? M{LQ[XNCVkeHUh?=
RKO NX6xbJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTVyLkK5JI5O MYPTRW5ITVJ?
KINGS-1 NGCyR3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXQSmVCUUN3ME21NU42PSCwTR?= NFzRWY5USU6JRWK=
EB-3 Ml;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDtTWM2OD13Mj62O{BvVQ>? M{fuc3NCVkeHUh?=
ARH-77 NVzPdGs1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLVTWM2OD13Mj64JI5O M37ae3NCVkeHUh?=
GCIY NHHGR41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vkVGlEPTB;NUOuOFYhdk1? MYjTRW5ITVJ?
NCI-H1304 MoLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLnTWM2OD13Nz6yNkBvVQ>? M3jxdHNCVkeHUh?=
KARPAS-299 M4\TbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTZzLkiyJI5O MWHTRW5ITVJ?
IA-LM NVzl[HZFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlnlTWM2OD14OD6xN{BvVQ>? MnfVV2FPT0WU
GI-1 M2HMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjISG1QUUN3ME23NE4{QSCwTR?= NUWxUlFLW0GQR1XS
TE-11 M4ToZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTd5LkG3JI5O MYjTRW5ITVJ?
LS-411N Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fUNWlEPTB;N{euOVchdk1? NXvOdXJuW0GQR1XS
no-11 MnXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXlTWM2OD16Mz6yOEBvVQ>? MYrTRW5ITVJ?
MV-4-11 NV7Je4ZyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TH[GlEPTB;OEOuO|Mhdk1? M{nlUXNCVkeHUh?=
BV-173 M3XmTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVy1d25wUUN3ME24N{46PyCwTR?= M13yVnNCVkeHUh?=
CMK MmPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPVe5dyUUN3ME24OE4yPiCwTR?= MWrTRW5ITVJ?
LC4-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXsbZVyUUN3ME24Ok44OiCwTR?= MkLJV2FPT0WU
COR-L279 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXNTWM2OD16Nz6yOUBvVQ>? NX\KSox1W0GQR1XS
NCI-H209 NVTPOpBUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYn3cWxoUUN3ME24O{41OSCwTR?= NWG0SHlCW0GQR1XS
Raji NUXRS|hQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrXflZKSzVyPUi5MlczKG6P MkDnV2FPT0WU
LB996-RCC NF31[21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUWwUmVYUUN3ME25N{41OyCwTR?= Ml\mV2FPT0WU
NCI-H526 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;xTWM2OD17Mz61PUBvVQ>? MWXTRW5ITVJ?
KGN M1XHfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTl4LkK5JI5O M4fub3NCVkeHUh?=
MOLT-4 NGrpNJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTl4Lke5JI5O M33pPXNCVkeHUh?=
PF-382 M3vkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHtOpdmUUN3ME25Ok44QSCwTR?= NYW5PGxZW0GQR1XS
BC-3 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Moi0TWM2OD17OT6xPEBvVQ>? MYfTRW5ITVJ?
KARPAS-422 M3TyOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPsdHFKSzVyPUGwNk4xQSCwTR?= MVzTRW5ITVJ?
SBC-1 MoLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFyNz63OUBvVQ>? M{jucXNCVkeHUh?=
LC-1F NWrU[I1JT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TJSmlEPTB;MUC4MlA2KG6P NVTFbFZLW0GQR1XS
GB-1 M2\Pfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jVfWlEPTB;MUC5MlAzKG6P MWHTRW5ITVJ?
SNB75 M3e2N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFzOT62PUBvVQ>? M{O3cHNCVkeHUh?=
BB65-RCC M1HjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\MZmlEPTB;MUG5Mlk{KG6P MnzvV2FPT0WU
NCI-N87 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnlc2FKSzVyPUGyNU46QCCwTR?= M1z0dXNCVkeHUh?=
IST-MEL1 NWCyb5JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPHTZFKSzVyPUGyNk4{QCCwTR?= NVHodGl2W0GQR1XS
HOP-62 M1jpOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NICyN29KSzVyPUGyOk45QSCwTR?= MnrQV2FPT0WU
ACN MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Xy[WlEPTB;MUS2Mlc2KG6P M1vKOHNCVkeHUh?=
DMS-114 NInlVotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkSwTWM2OD1zNUCuOlchdk1? M12xZXNCVkeHUh?=
MLMA MnyyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnvc5NjUUN3ME2xOVkvQDhibl2= MoDUV2FPT0WU
HT-144 M2PYOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXYT4xlUUN3ME2xOlUvPDNibl2= M1;P[3NCVkeHUh?=
C2BBe1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTF4Nz63OkBvVQ>? MkDNV2FPT0WU
L-428 MkfxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXiTWM2OD1zN{euO{BvVQ>? NITKWZlUSU6JRWK=
DU-4475 NWezXXU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{eyWWlEPTB;MUi3MlY5KG6P NIPwWnFUSU6JRWK=
CP67-MEL MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUnJR|UxRTF7OT6zPEBvVQ>? NIHOe5RUSU6JRWK=
MEG-01 NYWzWoJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3[4SWlEPTB;MkCxMlk3KG6P M{mwVHNCVkeHUh?=
IST-SL2 NHLvWG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzTPJpnUUN3ME2yNFgvPjNibl2= NF3ufGJUSU6JRWK=
ES8 M4\xc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;5NVBPUUN3ME2yNlUvQTRibl2= MlfEV2FPT0WU
COLO-800 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DVR2lEPTB;MkO1MlI5KG6P M1jIb3NCVkeHUh?=
MFH-ino NGDmbI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX25Z2pTUUN3ME2yN|UvQDRibl2= M{TsPXNCVkeHUh?=
OVCAR-4 NV7OT45HT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTJ|Nz6yOEBvVQ>? NVGyS2hsW0GQR1XS
PSN1 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHmTWM2OD1{NEKuO|Ehdk1? NEHMcFVUSU6JRWK=
EW-12 NGSzU3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnsXIVWUUN3ME2yOFMvOSCwTR?= M{iyT3NCVkeHUh?=
HCC1599 NGrNUWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfnXmdKSzVyPUK2NU41PyCwTR?= NVz4PIlQW0GQR1XS
SJSA-1 MmPIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fGSGlEPTB;MkexMlQ3KG6P NXfVb3h[W0GQR1XS
ST486 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHvHWFBKSzVyPUK5Ok4yPCCwTR?= NVLmfWxwW0GQR1XS
NOMO-1 NXvBfmNnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNyMD6yNUBvVQ>? NHTxO|BUSU6JRWK=
MN-60 NVLO[2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfaTWM2OD1|MEWuN|Ihdk1? M1vtVHNCVkeHUh?=
HCC1187 MoPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3FTWM2OD1|MEeuNlUhdk1? NHuyR3JUSU6JRWK=
SW982 M1fFUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnSzTWM2OD1|MUSuO|Uhdk1? MnvRV2FPT0WU
LB647-SCLC MmfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PFUmlEPTB;M{K4MlcyKG6P MWjTRW5ITVJ?
HC-1 NUDSSld{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTN|NT61JI5O M4f1S3NCVkeHUh?=
EHEB M3zh[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPSTWM2OD1|M{euOVIhdk1? NUC0PIZKW0GQR1XS
TUR NWLCbIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGewVYRKSzVyPUO2N{46PSCwTR?= MnXmV2FPT0WU
LU-139 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTN5OD6wNkBvVQ>? MYDTRW5ITVJ?
NB1 M2PBVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTWTWM2OD1|OESuOFUhdk1? M{jTeXNCVkeHUh?=
BB30-HNC MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRTN6OD6zNkBvVQ>? MnnrV2FPT0WU
HAL-01 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHxSoFoUUN3ME2zPFkvOjZibl2= MXjTRW5ITVJ?
K5 NIT5ZlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETjcWZKSzVyPUSxNU4{PyCwTR?= MkS2V2FPT0WU
MZ2-MEL NYPMUlBtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTBToViUUN3ME20NVMvPjRibl2= MkjUV2FPT0WU
RXF393 M{\pXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLJTWM2OD12MU[uOFUhdk1? NEPLRWFUSU6JRWK=
NCI-H1648 M2mwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzkdIF3UUN3ME20NVcvPTNibl2= Mn;NV2FPT0WU
TE-12 NXjqd3RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP0UolrUUN3ME20N|QvOjZibl2= MYLTRW5ITVJ?
EoL-1- NWPKcHJyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF;V[VFKSzVyPUSzO{46QCCwTR?= M3vsT3NCVkeHUh?=
JAR M{DLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPRVHRKSzVyPUSzPE43OiCwTR?= NVrXNnl5W0GQR1XS
DSH1 MnfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXGxO3NDUUN3ME20OVgvQTFibl2= M4jH[3NCVkeHUh?=
NCI-H187 Mkm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTR4Mj64NUBvVQ>? NFfweIZUSU6JRWK=
HCE-4 MmXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmDkTWM2OD12N{euOlYhdk1? M2n1SXNCVkeHUh?=
8-MG-BA MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG4TWM2OD13OEGuOVIhdk1? MWjTRW5ITVJ?
KLE NHu1O5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonTTWM2OD13OEWuNkBvVQ>? MXfTRW5ITVJ?
KNS-42 NFrBb5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rjOWlEPTB;NUi2MlgyKG6P MnrOV2FPT0WU
MSTO-211H NXzkfmpIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDZfVRKSzVyPU[wPU44PCCwTR?= NETqbGtUSU6JRWK=
GDM-1 M3TxSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPwTWM2OD14MUSuNFkhdk1? M{jXVnNCVkeHUh?=
TE-1 Ml7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTZ2Nj6xNkBvVQ>? NVTCXHV3W0GQR1XS
BT-474 M1POZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PZXGlEPTB;NkS3MlA3KG6P MlPOV2FPT0WU
KARPAS-45 Ml;nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTZ2Nz62JI5O Mlq1V2FPT0WU
MOLT-16 NX;KVYZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHOwWpRKSzVyPU[0O{46OyCwTR?= M3;GcHNCVkeHUh?=
KURAMOCHI M32zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDBUZBKSzVyPU[1O{42OSCwTR?= M2XrdHNCVkeHUh?=
K-562 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HvV2lEPTB;Nk[5MlUyKG6P NVLHboVtW0GQR1XS
EKVX M4rl[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTZ5Mj63NUBvVQ>? MY\TRW5ITVJ?
GAK MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZ5NT6zJI5O MXHTRW5ITVJ?
NCI-SNU-5 NHLGOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDUOotKSzVyPU[5NE4xOSCwTR?= NWLpb21rW0GQR1XS
NCI-H2126 MnvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlryTWM2OD15Mk[uPFchdk1? NHjocXJUSU6JRWK=
CTV-1 M4T6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDQTWM2OD15NESuPUBvVQ>? NVXVeoN4W0GQR1XS
SW962 NXHkU|R4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jtPWlEPTB;N{S4MlQ1KG6P NV3BcGdGW0GQR1XS
MONO-MAC-6 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIqxbZpKSzVyPUe1Ok46OyCwTR?= MnzKV2FPT0WU
NCI-H748 MlrMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:5WmlEPTB;N{W4Mlk6KG6P NEX4OpRUSU6JRWK=
NCI-H524 M13lUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDFS5FKSzVyPUe4NE44OyCwTR?= NFfLUG5USU6JRWK=
LS-123 NXPHNWlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTd7NT62PUBvVQ>? Mo\GV2FPT0WU
NB7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRThzND6xOEBvVQ>? M1P4eHNCVkeHUh?=
LS-1034 M3LVTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFyzZXVKSzVyPUiyPE46QCCwTR?= NVHPU4hVW0GQR1XS
TE-5 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTh6Mz61OkBvVQ>? M{O5c3NCVkeHUh?=
A704 NVO1bWx6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHe4eI5KSzVyPUi5PU4yPSCwTR?= NVzZ[Wg3W0GQR1XS
TK10 NYXoN5VnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnRRpNYUUN3ME25NVYvODNibl2= NXPaU2NIW0GQR1XS
NCI-H345 NYnrTVE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlLzTWM2OD17NEOuNlIhdk1? NInGO5JUSU6JRWK=
CGTH-W-1 MnfrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTl2OD6xN{BvVQ>? NHTLU2xUSU6JRWK=
NCI-H510A NUDreVljT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTl6NT6xNkBvVQ>? M2P5XnNCVkeHUh?=
NCI-H1963 NYrhVWxOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILoXZZKSzVyPUGuNFMzQTJizszN MlXNV2FPT0WU
SCC-3 MorMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX3jWJA2UUN3ME2xMlA{PDF2IN88US=> M4THdHNCVkeHUh?=
EW-11 NUXpbWl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HYRmlEPTB;MT6wPFc1OyEQvF2= M2nmbHNCVkeHUh?=
CPC-N M3HPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWe0Xm5pUUN3ME2xMlA5QCEQvF2= NInPZmlUSU6JRWK=
NCI-H1417 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3y4fWlEPTB;MT6xNlI3KM7:TR?= M37VW3NCVkeHUh?=
DG-75 NF;qc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HZcWlEPTB;MT6xOlI5PSEQvF2= NGLXV|RUSU6JRWK=
HD-MY-Z NHzPR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTGTWM2OD1zLkG2OFE3KM7:TR?= M4n4bnNCVkeHUh?=
ATN-1 Mmf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwMk[yNFkh|ryP NGTDNmZUSU6JRWK=
KM-H2 M1XyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1zLkK2OFA5KM7:TR?= Mn6wV2FPT0WU
NCI-H2081 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjVR3dKSzVyPUGuNlY3OzdizszN NWj3So9ZW0GQR1XS
HL-60 MofMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTFwMk[5OVkh|ryP M2r3[HNCVkeHUh?=
DB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTFwMkeyOFIh|ryP NH\UcYtUSU6JRWK=
NCI-H1522 MnTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzJfWV{UUN3ME2xMlI5QDh5IN88US=> NHzJfJVUSU6JRWK=
AM-38 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTFwM{C3NkDPxE1? NFfL[XNUSU6JRWK=
NCI-H446 MnTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTFwM{KxNlEh|ryP Ml3hV2FPT0WU
SU-DHL-1 M2T5NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITkRVJKSzVyPUGuN|I5ODFizszN NIjOSGFUSU6JRWK=
NH-12 M1TGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTFwM{[zO|Qh|ryP NU\UZXVIW0GQR1XS
DMS-79 NXPhN3B4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\ZRZh5UUN3ME2xMlM3QDZ4IN88US=> NWT1fFBuW0GQR1XS
NCI-H716 M3fr[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPXS5EyUUN3ME2xMlM5QTh4IN88US=> MkjjV2FPT0WU
ML-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fsUmlEPTB;MT60NVUzQSEQvF2= MUXTRW5ITVJ?
NB10 NFP5cVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnW0TWM2OD1zLkS2OlMzKM7:TR?= MlPCV2FPT0WU
ONS-76 M4TMbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmHYTWM2OD1zLkWzOVY6KM7:TR?= MmS0V2FPT0WU
LOUCY NGjUTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfa[3lZUUN3ME2xMlU1PjV5IN88US=> M3zYeHNCVkeHUh?=
SCLC-21H MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYDPPVZNUUN3ME2xMlU5PTh{IN88US=> NX;iem93W0GQR1XS
TGW NEjYS4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzIfVFGUUN3ME2xMlY{QTd3IN88US=> M{nONnNCVkeHUh?=
LXF-289 M4XLXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnz2TWM2OD1zLkezNlY5KM7:TR?= MVfTRW5ITVJ?
BB49-HNC NHS0c4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DiOGlEPTB;MT63N|U5PiEQvF2= NF;QPGZUSU6JRWK=
NCI-H747 NETxTm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHBTWM2OD1zLke1N|Q3KM7:TR?= NUjQWnNPW0GQR1XS
LU-165 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX32V4t1UUN3ME2xMlg1QTh4IN88US=> NVTKN4JqW0GQR1XS
OMC-1 NEfLflFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[zO2lEPTB;MT65OVA3PiEQvF2= M1z1b3NCVkeHUh?=
RCC10RGB Mki4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLHOmZKSzVyPUGuPVU5OTdizszN MoOxV2FPT0WU
SW684 NVmxSIZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfGTWM2OD1zLkm2NFk6KM7:TR?= NVLmVIdbW0GQR1XS
TE-8 MoDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorqTWM2OD1{LkC1OVU6KM7:TR?= M2LabXNCVkeHUh?=
SK-N-DZ MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2[5SWlEPTB;Mj6xN|I4PCEQvF2= MUnTRW5ITVJ?
EVSA-T M{fhZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwMUezNVUh|ryP M1fO[HNCVkeHUh?=
KASUMI-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3uwOGlEPTB;Mj6xPFgyPSEQvF2= MoX6V2FPT0WU
NKM-1 MofZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTJwMkW0O|Ih|ryP M2HOWHNCVkeHUh?=
CAL-148 MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;ZdItkUUN3ME2yMlM{PjF2IN88US=> MWXTRW5ITVJ?
NCI-H64 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LZ[WlEPTB;Mj6zOFI{OiEQvF2= MnHnV2FPT0WU
KNS-81-FD NFXxW|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;yTWM2OD1{LkO2OlIh|ryP NX;kVYZ{W0GQR1XS
KM12 M{exbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJwNEC4N|kh|ryP MVrTRW5ITVJ?
SW954 NW\CfWJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4rO[GlEPTB;Mj60O|c4QSEQvF2= MkHWV2FPT0WU
NCI-H1395 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;2T5JXUUN3ME2yMlUzPjR3IN88US=> NVGxfFd6W0GQR1XS
DJM-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGKzSGFKSzVyPUKuOlA3OyEQvF2= NWPYNVEzW0GQR1XS
COLO-668 NYTTNJNIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTJwOEK2PVUh|ryP NFTCemhUSU6JRWK=
NCI-H1436 M4q1dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XEeWlEPTB;Mj64OVYyPSEQvF2= MVXTRW5ITVJ?
LB2241-RCC MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXVTWM2OD1{Lki2PFM6KM7:TR?= MknOV2FPT0WU
GT3TKB MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXHV|lLUUN3ME2yMlg6ODV3IN88US=> NWfjPZJlW0GQR1XS
COLO-824 MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZVmlEPTB;Mj64PVc3QCEQvF2= NWqyclRnW0GQR1XS
ES1 NFGzS3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWL5VFRoUUN3ME2yMlg6QDd7IN88US=> Mon6V2FPT0WU
LB771-HNC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy2e3NKSzVyPUKuPVA6PDZizszN M1vKUHNCVkeHUh?=
GI-ME-N MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFm1TlhKSzVyPUOuNFA6ODRizszN NXTQV2Z3W0GQR1XS
NALM-6 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTNwMEC5N|Mh|ryP NFnZOWJUSU6JRWK=
LU-134-A NWLzboE6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrpPHpsUUN3ME2zMlA2PDJ3IN88US=> M33oSXNCVkeHUh?=
DMS-153 NXjaSYhsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHG1eHFKSzVyPUOuNFU5OjRizszN MnT3V2FPT0WU
MZ1-PC M4nqOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTNwMEmwO|gh|ryP NVTyTFdxW0GQR1XS
NCI-H1155 MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjm[otKSzVyPUOuNVE3OSEQvF2= NVK0Zox6W0GQR1XS
CAS-1 NFqxclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3KSFZKSzVyPUOuNVM4ODdizszN M2XmVHNCVkeHUh?=
D-502MG MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn6WG9UUUN3ME2zMlE1OzlizszN M2\jZ3NCVkeHUh?=
NCI-H2141 M3LRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfGenRKSzVyPUOuNVc1PTJizszN NXfCbHV3W0GQR1XS
NB6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\Je2lEPTB;Mz6xPFI2QSEQvF2= MXfTRW5ITVJ?
NCCIT MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzXbZJKSzVyPUOuNlE5ODlizszN NGjFSWJUSU6JRWK=
NB69 MlLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHpNo5RUUN3ME2zMlMyQDlzIN88US=> MmrjV2FPT0WU
JVM-2 NVjxR5BDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETNcWxKSzVyPUOuN|Y1OzNizszN M2ntR3NCVkeHUh?=
K052 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGnxdmdKSzVyPUOuN|c6PjhizszN NITjWVZUSU6JRWK=
HCC2157 NHnJNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorXTWM2OD1|LkWzNlI5KM7:TR?= M4nLbnNCVkeHUh?=
KMOE-2 NXzEUYdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLXeIRKSzVyPUOuOVQzPDJizszN NEP5fVNUSU6JRWK=
SF268 NEfCXpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3cmlEPTB;Mz63NVU2PCEQvF2= NYXi[2FuW0GQR1XS
CHP-126 NGL1[3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTNwN{[0OVgh|ryP M2PrbHNCVkeHUh?=
CP66-MEL NHSzbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrqOoZKSzVyPUOuO|kxQTRizszN MXHTRW5ITVJ?
NCI-H69 MmPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTnTWM2OD12LkCxPVM3KM7:TR?= NIjvdWZUSU6JRWK=
A253 NIr0TFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzUblc6UUN3ME20MlAzOTBzIN88US=> NEHTVoZUSU6JRWK=
NB14 NF\rOIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;iO2RpUUN3ME20MlExPDd7IN88US=> NVm5OnhSW0GQR1XS
NCI-H1694 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTRwMUOxNVIh|ryP M{XDfXNCVkeHUh?=
NCI-H2196 Moq4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIThU2NKSzVyPUSuNVcyPjlizszN MXzTRW5ITVJ?
TE-9 Mlu3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYq2e|Q6UUN3ME20MlE4PTh{IN88US=> NYHETFJRW0GQR1XS
D-283MED MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{ntUGlEPTB;ND6xPFg1KM7:TR?= NHXpUYdUSU6JRWK=
OCI-AML2 M1rjPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTRwMUm0PFkh|ryP NVXDWmpFW0GQR1XS
D-263MG MlvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2[0PGlEPTB;ND6yNlk3OSEQvF2= MV;TRW5ITVJ?
MPP-89 MkO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvWeIdZUUN3ME20MlI4OzB2IN88US=> M2HPR3NCVkeHUh?=
LAMA-84 NWTjcFluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVj1[pNJUUN3ME20MlMxPDJzIN88US=> M{izfXNCVkeHUh?=
LB373-MEL-D MnPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnDTWM2OD12LkO2O|g6KM7:TR?= MV3TRW5ITVJ?
UACC-257 NHriS2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXNR2FZUUN3ME20MlM6PTN2IN88US=> M3XVdXNCVkeHUh?=
MC-CAR M4DGXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLvV3J1UUN3ME20MlQ{QTlizszN M4C0UnNCVkeHUh?=
COLO-320-HSR MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mni4TWM2OD12LkS0OFI4KM7:TR?= NHrafYxUSU6JRWK=
P30-OHK MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7FXXZ3UUN3ME20MlY3PThzIN88US=> MVPTRW5ITVJ?
UACC-812 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnuyTWM2OD12Lk[5NVYyKM7:TR?= MnjJV2FPT0WU
CTB-1 NYWzRYo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SzV2lEPTB;ND63NVU2PSEQvF2= MYfTRW5ITVJ?
ALL-PO NIm2UpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTRwOESwO|ch|ryP NIrOUoFUSU6JRWK=
SK-MEL-2 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYTJR|UxRTRwOE[5OVUh|ryP MlzNV2FPT0WU
TC-YIK NX3tUok1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHH2W41KSzVyPUSuPVc6PDJizszN M4LIS3NCVkeHUh?=
NCI-H1882 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTVwMEKwNFEh|ryP MkTCV2FPT0WU
MHH-CALL-2 NX7RZ|RWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvnZnlKSzVyPUWuNFUxPDJizszN MoL5V2FPT0WU
U-87-MG NFnyWFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rhVmlEPTB;NT6wPVQ3PiEQvF2= M3LyUnNCVkeHUh?=
NCI-H1092 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmLtTWM2OD13LkK2OVU2KM7:TR?= MmDqV2FPT0WU
TE-441-T NWLHZZlCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnf2TWM2OD13LkK3PFIh|ryP MYfTRW5ITVJ?
SK-MEL-1 NWTkeYFiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDOSlg5UUN3ME21MlI6ODR2IN88US=> MnzOV2FPT0WU
EW-22 MnfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV72[XZVUUN3ME21MlI6PDZ4IN88US=> MV;TRW5ITVJ?
MZ7-mel MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTVwNEC2PVEh|ryP MXXTRW5ITVJ?
LP-1 NFz4fW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLFTWM2OD13LkSxNlkyKM7:TR?= MU\TRW5ITVJ?
NCI-SNU-16 MnzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWG4TJpGUUN3ME21MlY1ODd2IN88US=> NWHzfnpsW0GQR1XS
LU-65 NF33cWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlvxTWM2OD13Lke2N|c{KM7:TR?= NX:4dnJCW0GQR1XS
CW-2 MnH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkniTWM2OD13Lki1PVU6KM7:TR?= NXfQfIdRW0GQR1XS
WSU-NHL M3;jOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnr4TWM2OD13Lkm1NVc1KM7:TR?= MkX3V2FPT0WU
IST-MES1 M17F[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PobWlEPTB;NT65OVQ1OyEQvF2= NFTIO|hUSU6JRWK=
U-266 MlnnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0VWR4UUN3ME21Mlk5OjB{IN88US=> M1zYZ3NCVkeHUh?=
TALL-1 M37KW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfuXmRKSzVyPU[uNVQ3QDhizszN MoHnV2FPT0WU
Calu-6 M{\sPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFfFUVhKSzVyPU[uNVU{OTZizszN MVLTRW5ITVJ?
MMAC-SF NYTmfHJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTOTWM2OD14LkG4OVU3KM7:TR?= NXnqV5I6W0GQR1XS
NCI-H82 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLlOZlKSzVyPU[uNlA1QDlizszN M3foPHNCVkeHUh?=
RS4-11 NE\EPIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fwOmlEPTB;Nj6yOVg6PyEQvF2= NIHORW9USU6JRWK=
SNU-C2B MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTZwNEC5Olkh|ryP NVf3dlZ5W0GQR1XS
BOKU NF3q[ndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHn[GlKSzVyPU[uOFc2QTdizszN MnTNV2FPT0WU
C8166 M3vD[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PiTmlEPTB;Nj61OVkyOiEQvF2= NIDU[mxUSU6JRWK=
D-247MG MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkj2TWM2OD15LkC0N|Q4KM7:TR?= NXHZXI95W0GQR1XS
EW-18 M1XuOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Lhe2lEPTB;Nz6wO|I6OiEQvF2= MlvEV2FPT0WU
KG-1 M4XXWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDNfmtvUUN3ME23MlYzPzN6IN88US=> NH31WHpUSU6JRWK=
REH MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmPjTWM2OD15Lk[4NVA6KM7:TR?= NVnvXnBPW0GQR1XS
U-698-M NYDmSnlPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPkTWM2OD15Lki0N|E2KM7:TR?= NIn0TolUSU6JRWK=
KP-N-RT-BM-1 NXzDRmdlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTdwOUOwNlkh|ryP NUT5dmpEW0GQR1XS
MS-1 NYLQcWNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PrfGlEPTB;Nz65OlA1OSEQvF2= Mly4V2FPT0WU
SNU-C1 NE\LRYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXT[VJKSzVyPUeuPVgyQTJizszN MY\TRW5ITVJ?
SK-MM-2 NYfHfYRCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor2TWM2OD16LkK2NFY2KM7:TR?= NFX1UnhUSU6JRWK=
LAN-6 NEe4ZWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmezTWM2OD16LkOwNFAyKM7:TR?= M3H5OHNCVkeHUh?=
NEC8 M2LMN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3[YNKSzVyPUiuN|A3QTFizszN MV;TRW5ITVJ?
NCI-H1770 NGDybYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILkcFhKSzVyPUiuN|gxODJizszN M2DzdXNCVkeHUh?=
D-336MG Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XiW2lEPTB;OD60NFEyPiEQvF2= NXvJWY9bW0GQR1XS
COLO-829 NUPmZWpPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MleyTWM2OD16LkS4PFc6KM7:TR?= NYPIdI5tW0GQR1XS
LS-513 NVvrZlVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\nSGlEPTB;OD61PVU6QSEQvF2= NWjHTIdsW0GQR1XS
YT MkjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXUbnFKSzVyPUiuOlI1OjdizszN MlPvV2FPT0WU
EW-24 MonFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NID5WZJKSzVyPUiuO|Y2PCEQvF2= NYrzW|FlW0GQR1XS
IST-SL1 NVP2Smg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vXcmlEPTB;OD64OlU1OyEQvF2= MmGzV2FPT0WU
CA46 M3TUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU[4[GFxUUN3ME24Mlk2ODl6IN88US=> M4HxTXNCVkeHUh?=
NCI-H1838 M3;IWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIjLNIdKSzVyPUiuPVg3ODJizszN NELkR2JUSU6JRWK=
NCI-H719 M{jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXzTWM2OD17LkK1Nlc6KM7:TR?= NGXa[FVUSU6JRWK=
HCE-T MofaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3T1TWlEPTB;OT6zNFg2OSEQvF2= NXjCcFVDW0GQR1XS
A498 MnO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PXSGlEPTB;OT6zOlEzPCEQvF2= MX3TRW5ITVJ?
LB831-BLC MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTlwN{[1NlEh|ryP MXvTRW5ITVJ?
SKM-1 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHNTWM2OD17Lki1PVY{KM7:TR?= M1nxO3NCVkeHUh?=
THP-1 NHS1dHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;ZeXhsUUN3ME25Mlk3QTF6IN88US=> MorpV2FPT0WU
SHP-77 M{jSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ZTWM2OD1zMD60NFch|ryP NEnSbm5USU6JRWK=
EW-3 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXxTWM2OD1zMD62Nlg6KM7:TR?= MWXTRW5ITVJ?
KY821 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HF[GlEPTB;MUCuO|Y{KM7:TR?= M{\i[3NCVkeHUh?=
NCI-SNU-1 NFnzeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTFzLkCyNVch|ryP NXS0fWJ3W0GQR1XS
HCC2218 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDyTWM2OD1zMT6zPVg3KM7:TR?= MUXTRW5ITVJ?
IM-9 M4HjZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;ybZZKSzVyPUGxMlUyODZizszN Mle3V2FPT0WU
NCI-H889 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXB[nRKSzVyPUGxMlU{OTNizszN NI\IPHBUSU6JRWK=
HDLM-2 M{GyV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITqZnNKSzVyPUGyMlQyPTlizszN M2Xz[XNCVkeHUh?=
LB2518-MEL NInuTnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELwWFdKSzVyPUGyMlY5OTVizszN M{K1enNCVkeHUh?=
NCI-H23 NFXVZ2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\MUVRKSzVyPUGzMlI1OjVizszN NXH6dmw1W0GQR1XS
NB17 NVXoOnBqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vq[GlEPTB;MUOuOFU4QSEQvF2= MX;TRW5ITVJ?
NCI-H322M M{nuPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPSU4NKSzVyPUG0MlQxPjhizszN MWHTRW5ITVJ?
SUP-T1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTF2LkSxN{DPxE1? NICyS|FUSU6JRWK=
ES3 M4HKTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTF3LkC3NFMh|ryP NYfQcYVkW0GQR1XS
ES5 NHW1V4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF3LkC3PFch|ryP M3zmNXNCVkeHUh?=
NCI-H1650 Mn23S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH2TWM2OD1zNT60PVc6KM7:TR?= NXjCUI9[W0GQR1XS
NCI-H226 NGHrXIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF3Lki3Olgh|ryP NHHLR2JUSU6JRWK=
COR-L88 NFXBTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3THS2lEPTB;MU[uN|E1KM7:TR?= Mn\wV2FPT0WU
SCC-15 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTF4LkO4Olkh|ryP NU[2V|Q4W0GQR1XS
GOTO NYDoUmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1;0[mlEPTB;MU[uOFc6OyEQvF2= NIOyW3FUSU6JRWK=
SIMA M2jSTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPpbo9uUUN3ME2xOk41QDB{IN88US=> M1XoenNCVkeHUh?=
NCI-H1299 M3zreWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4f2ZWlEPTB;MUeuNVU6OSEQvF2= NEPDTJVUSU6JRWK=
NCI-H1581 M{nTXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KxZmlEPTB;MUeuOFIyQSEQvF2= MYHTRW5ITVJ?
MHH-NB-11 M{[5OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlu3TWM2OD1zNz65Olg{KM7:TR?= Mn;QV2FPT0WU
MFM-223 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDEOIJqUUN3ME2xPE4xPTN6IN88US=> NWPkdIhyW0GQR1XS
ES7 NEOzR5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPoTWM2OD1zOD61OFMyKM7:TR?= MnLyV2FPT0WU
JVM-3 M1Tjemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1XFfmlEPTB;MUiuO|E4KM7:TR?= NWDpTJJ[W0GQR1XS
RL MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTJyLkO4PEDPxE1? NULjVphWW0GQR1XS
EC-GI-10 NGGwclJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2HmbGlEPTB;MkGuNlA1OSEQvF2= MYTTRW5ITVJ?
LNCaP-Clone-FGC MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi1bFRrUUN3ME2yNU43PzZ6IN88US=> NVXtRZR1W0GQR1XS
IMR-5 Moj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTETWM2OD1{MT64OFk1KM7:TR?= MYDTRW5ITVJ?
KP-N-YS NVjIPIl7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvnc2pKSzVyPUKxMlg4PSEQvF2= NVHKZnJuW0GQR1XS
Mo-T M{P3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fOemlEPTB;MkKuNlE5PSEQvF2= MX\TRW5ITVJ?
NCI-H128 NGK3T3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFGwSopKSzVyPUKzMlU5PTNizszN NUjHUJBMW0GQR1XS
RH-1 M17WZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTJ|Lke4OlYh|ryP NFTSNmVUSU6JRWK=
NCI-H2171 NYS0bJhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LUfmlEPTB;MkSuNlQ5PSEQvF2= MkfwV2FPT0WU
RPMI-8866 M1i3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrFUIdQUUN3ME2yOk44PDJizszN MWjTRW5ITVJ?
SK-N-FI Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLITWM2OD1{Nz6zPFEyKM7:TR?= NYjGb493W0GQR1XS
LOXIMVI NFvOR4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HpR2lEPTB;MkeuPFA2OSEQvF2= MWfTRW5ITVJ?
P31-FUJ NXT5RYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYTxT4dxUUN3ME2zNU42Ozd2IN88US=> MYLTRW5ITVJ?
KMS-12-PE NFzndnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTR7LkWzNFIh|ryP NHjOWIdUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]

+ Expand

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]

+ Expand
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Formulation: Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 2% DMSO+30% PEG 300+5% Tween 80+ddH2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989,NSC-2260804

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00062712 Completed Kidney Transplantation National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|National Institutes of Health Clinical Center (CC) June 9, 2003 Phase 2
NCT01814059 Terminated Eosinophilic Gastroenteritis|Eosinophilic Esophagitis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) March 7, 2013 Phase 1
NCT01303965 Active, not recruiting Multiple Myeloma Sherif S. Farag|Celgene Corporation|Indiana University February 7, 2011 Phase 1|Phase 2
NCT02891603 Not yet recruiting Graft Vs Host Disease|GVHD H. Lee Moffitt Cancer Center and Research Institute April 30, 2017 Phase 1|Phase 2
NCT02423915 Recruiting Leukemia|Lymphoma M.D. Anderson Cancer Center|National Cancer Institute (NCI)|Targazyme, Inc.|Cancer Prevention Research Institute of Texas July 30, 2015 Phase 1|Phase 2
NCT01182883 Withdrawn Brain Stem Neoplasms|Glioma|Pinealoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 28, 2010 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

Related mTOR Products

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID